CM518D1 / Keymed Biosciences - LARVOL DELTA

First-in-human study of CM518D1: a novel CDH17 ADC in advanced solid tumors (ESMO 2026) - No abstract available

ADC • First-in-human • Metastases • P1 data • Oncology • Solid Tumor • CDH17

Study of CM518D1 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=434 | Recruiting | Sponsor: Keymed Biosciences Co.Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

Study of CM518D1 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=434 | Not yet recruiting | Sponsor: Keymed Biosciences Co.Ltd

New P1/2 trial • Solid Tumor

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers (PRNewswire) - "Keymed Biosciences Inc....received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and is currently undergoing Phase I/II clinical trials in China for the treatment of solid tumors....Future studies aim to provide a more precise, effective, and safe therapeutic option for patients worldwide with gastrointestinal cancers."

New P1/2 trial • Gastrointestinal Cancer • Solid Tumor

Keymed Biosciences Announces Annual Results of 2024 (GlobeNewswire) - "CM518D1 (CDH17 ADC): We submitted IND application to CDE, and planned to conduct a multi-center, open-label Phase I/II clinical trial for evaluation of CM518D1 in treatment of patients with advanced solid tumors."

New P1/2 trial • Solid Tumor